The FDA approved aducanumab, to be sold under the brand name Aduhelm, this week over the objections of its advisory Peripheral and Central Nervous System Drugs Advisory Committee.
Mayo Clinic neurologist Dr. David Knopman told CNN Wednesday he had resigned from the committee in protest.
“I resigned from the PCNS committee because if I ever were asked to serve on a future panel, I wouldn’t have wanted to be treated in the disrespectful way that the aducanumab external advisers were treated,” he said via email.
“While I disagree with the decision to approve aducanumab, we in the clinical care…
Connect with us on our socials: